Methods for drug discovery, disease treatment, and diagnosis using metabolomics

• US 20070178599A1
• Filed: 03/27/2007
• Published: 08/02/2007
• Est. Priority Date: 04/14/2000
• Status: Active Grant

• Current Assignee: Cornell Research Foundation Incorporated (Cornell University), Metabolon Incorporated
• Original Assignee: Metabolon Incorporated
• Inventors: Kaddurah-Daouk, Rima, Kristal, Bruce
• Granted Patent: US 7,553,616 B2
• Time in Patent Office: Days
• US Class Current: 436/86
• CPC Class Codes: G01N 2800/304 Mood disorders, e.g. bipolar, depression
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/4833 of solid biological material, e.g. tissue samples, cell cultures tissue in vivo A61B5/00; cell suspensions G01N33/48735
• CPC Class Codes: G01N 33/5011 for testing antineoplastic activity
• CPC Class Codes: G01N 33/5038 involving detection of metabolites per se
• CPC Class Codes: G01N 33/5079 Mitochondria
• CPC Class Codes: G01N 33/5091 for testing the pathological state of an organism
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
• CPC Class Codes: Y02A 90/10 Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

The small molecule profiles of cells are compared to identify small molecules which are modulated in altered states. Cellular small molecule libraries, methods of identifying tissue sources, methods for treating genetic and non-genetic diseases, and methods for predicting the efficacy of drugs are also discussed.

Claims

1. A method for metabolomically identifying small molecules indicative of an oncological disorder, comprising:

obtaining a small molecule profile from a subject suffering from said oncological disorder; and

comparing the small molecule profile from the subject to a standard small molecule profile, thereby identifying small molecules indicative of said oncological disorder.

2. The method of claim 1, wherein said subject is a human.

3. The method of claim 1, wherein said small molecule profile is obtained from a subject'"'"'s tissue, or biological fluids.

4. The method of claim 3, wherein said tissue is stomach, colon, skin, breast, muscle, lung, kidney or liver tissue.

5. The method of claim 3, wherein said tissue comprises a tumor.

6. The method of claim 5, wherein said tumor is malignant.

7. The method of claim 1, wherein said small molecule profile is obtained from said subject'"'"'s blood, spinal fluid, serum, cells, cellular organelles, urine, interstitial fluid, or saliva.

8. The method of claim 1, wherein said small molecule profiles are obtained using one or more of the following:

HPLC, TLC, electrochemical analysis, mass spectroscopy, refractive index spectroscopy (RI), Ultra-Violet spectroscopy (UV), fluorescent analysis, radiochemical analysis, Near-InfraRed spectroscopy (Near-IR), Nuclear Magnetic Resonance spectroscopy (NMR), gas chromatography (GC) and Light Scattering analysis (LS).

9. The method of claim 1, wherein said oncological disorder is leukemia, brain cancer, pancreatic cancer, prostate cancer, liver cancer, stomach cancer, colon cancer, throat cancer, breast cancer, ovarian cancer, skin cancer, melanoma, lymphoma, or a cancerous tumor.

10. A method for metabolomically predicting whether a subject is predisposed to having an oncological disorder, comprising:

obtaining a small molecule profile from the subject; and

comparing the small molecule profile from the subject to a standard small molecule profile, thereby predicting whether a subject is predisposed to having an oncological disorder.

11. The method of claim 10, wherein said subject is a human.

12. The method of claim 10, wherein said small molecule profile is obtained from a subject'"'"'s tissue or biological fluids.

13. The method of claim 12, wherein said tissue is stomach, colon, skin, breast, muscle, lung, kidney or liver tissue.

14. The method of claim 12, wherein said subject'"'"'s tissue is a tumor.

15. The method of claim 14, wherein said tumor is malignant.

16. The method of claim 10, wherein said small molecule profile is obtained from said subject'"'"'s blood, spinal fluid, serum, cells, cellular organelles, urine, interstitial fluid, or saliva.

17. The method of claim 10, wherein said small molecule profiles are obtained using one or more of the following:

HPLC, TLC, electrochemical analysis, mass spectroscopy, refractive index spectroscopy (RI), Ultra-Violet spectroscopy (UV), fluorescent analysis, radiochemical analysis, Near-InfraRed spectroscopy (Near-IR), Nuclear Magnetic Resonance spectroscopy (NMR), gas chromatography (GC) and Light Scattering analysis (LS).

18. The method of claim 10, wherein said oncological disorder is leukemia, brain cancer, pancreatic cancer, prostate cancer, liver cancer, stomach cancer, colon cancer, throat cancer, breast cancer, ovarian cancer, skin cancer, melanoma, lymphoma, or a cancerous tumor.